Page 346 of 400: studies 3,451 to 3,460 of 3,999, newest first. Back to the serotonin overview
Anesthesiology October 1, 2011 Edgar Alfonso Romero-Sandoval 21 citations
Dartmouth Medical School, Dartmouth College, Lebanon, New Hampshire. edgar.a.romero-sandoval@dartmouth.eduA LARGE population of patients concomitantly experiences chronic pain and depression or symptoms of depression (52% in pain clinics, or 85% in chronic facial pain dental clinics, for example).1How these two syndromes coexist, interact, reinforce each other, and/or are maintained is poorly...
Psychopharmacology October 2011 Una D. Mccann, Robert R Edwards, Michael T Smith et al.
(±)3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has potential to damage brain serotonin (5-HT) neurons in humans. Brain 5-HT neurons play a role in pain modulation, yet little is known about long-term effects of MDMA on pain function. Notably, MDMA users have been shown to have altered sleep, a phenomenon that can lead to altered pain modulation. This study...
Journal of Neuroscience Research September 21, 2011 Elena Puerta, Lucía Barros-Miñones, Isabel Hervias et al. 17 citations
Sildenafil, given shortly before 3,4-methylenedioxymethamphetamine (MDMA), affords protection against 5-hydroxytryptamine (5-HT) depletions caused by this amphetamine derivative by an acute preconditioning-like mechanism. Because acute and delayed preconditionings do not share the same mechanisms, we investigated whether sildenafil would also protect the 5-HT system of the rat if given 24 hr...
Human Brain Mapping September 16, 2011 Dráulio Barros de Araújo, Sidarta Ribeiro, Guillermo Cecchi et al. 241 citations
Abstract The hallucinogenic brew Ayahuasca, a rich source of serotonergic agonists and reuptake inhibitors, has been used for ages by Amazonian populations during religious ceremonies. Among all perceptual changes induced by Ayahuasca, the most remarkable are vivid “seeings.” During such seeings, users report potent imagery. Using functional magnetic resonance imaging during a closed‐eyes...
The International Journal of Neuropsychopharmacology September 12, 2011 Oz Malkesman, Daniel Austin, Tyson Tragon et al. 91 citations
Research suggests that dysfunctional glutamatergic signalling may contribute to depression, a debilitating mood disorder affecting millions of individuals worldwide. Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist, exerts rapid antidepressant effects in approximately 70% of patients. Glutamate evokes the release of D-serine from astrocytes and neurons, which then acts as a...
Psychopharmacology September 2011 Masakuni Horiguchi, Mei Huang, Herbert Y. Meltzer
Subchronic administration to rodents of the N-methyl-D-aspartate non-competitive antagonist, phencyclidine (PCP), impairs novel object recognition (NOR). Atypical antipsychotic drugs (APDs) reverse the effects of subchronic PCP on NOR. The effect of metabotropic glutamate₂/₃ receptor (mGlu₂/₃) agonists upon NOR is unknown. We tested the hypotheses that the mGlu₂/₃ agonist, LY379268, by itself,...
Behavioural Pharmacology September 1, 2011 Mary Melissa Peet, Lisa E Baker 21 citations
Salvinorin A, the main active component of Salvia divinorum, is a potent and selective κ opioid receptor agonist. Synthetic derivatives of this substance may be useful in the development of medicinal treatments for pain, mood disorders, and drug dependence. Such developments require extensive preclinical screening of these compounds. The drug discrimination assay is a valuable method for...
Progress in Neuro-Psychopharmacology and Biological Psychiatry August 15, 2011 Kenji Hashimoto
Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects millions of individuals worldwide. Currently available antidepressants are known to affect the monoaminergic (e.g., serotonin, norepinephrine, and dopamine) systems in the brain. Accumulating evidence suggests that the glutamatergic neurotransmission via the excitatory amino acid glutamate also plays an...
Psychopharmacology August 12, 2011 Rafael G. Dos Santos, Eva Grasa, Marta Valle et al. 139 citations
RationaleAyahuasca is an Amazonian tea containing the natural psychedelic 5-HT(2A/2C/1A) agonist N,N-dimethyltryptamine (DMT). It is used in ceremonial contexts for its visionary properties. The human pharmacology of ayahuasca has been well characterized following its administration in single doses.ObjectivesTo evaluate the human pharmacology of ayahuasca in repeated doses and assess the...
Journal of Neuroinflammation August 6, 2011 O'Shea Esther, Rubio Ana, Mayado Andrea et al. 28 citations
Abstract Background 3,4-Methylenedioxymethamphetamine (MDMA) produces a neuroinflammatory reaction in rat brain characterized by an increase in interleukin-1 beta (IL-1β) and microglial activation. The CB2 receptor agonist JWH-015 reduces both these changes and partially protects against MDMA-induced neurotoxicity. We have examined MDMA-induced changes in IL-1 receptor antagonist (IL-1ra)...